Which company produces Vigabatrin and its production background?

Vigabatrin is a drug mainly used to treat refractory epilepsy, especially in patients with infantile spasms and partially drug-resistant focal epilepsy. It inhibits γ-aminobutyric acid transaminase (GABA-T) and increases the concentration of γ-aminobutyric acid (GABA) in the central nervous system, thereby enhancing the effect of inhibitory neurotransmitters and helping to control epileptic seizures. Due to its unique mechanism of action, Vigabatrin occupies an important position in the field of epilepsy treatment.

The drug was originally developed by the French pharmaceutical company Sanofi-Aventis and has since been gradually promoted and used around the world. With in-depth research on the efficacy of the drug, another Irish-based pharmaceutical company Horizon Therapeutics plc (formerly a business of Mallinckrodt) has also participated in its related marketing. In the U.S. market, the commercialization of Vigabatrin is mainly carried out by Lundbeck Company (Lundbeck Pharmaceuticals, headquartered in Denmark). This company focuses on the research and development and production of drugs for central nervous system diseases, making Vigabatrin widely used in many countries and regions around the world.

From a production background, the original intention of Vigabatrin’s research and development was to find a new mechanism drug that could effectively control refractory epileptic seizures. In the 1980s, traditional anti-epileptic drugs were ineffective or even resistant to some patients, so the research and development team turned their attention to regulating neurotransmitter metabolism. The emergence of Vigabatrin has filled the gap in this field, especially in the treatment of infantile spasms. It has made breakthrough progress and has been approved as one of the preferred treatment options in many countries.

It should be pointed out that although vigabatrin has important value in the treatment of epilepsy, its potential adverse reactions, especially the risk of visual field defects related to retinal toxicity, limit its popular use. Therefore, drug regulatory agencies in various countries require strict ophthalmic monitoring during use. Even so, Vigabatrin is still an indispensable treatment option for some patients with refractory epilepsy, reflecting the efforts and responsibility of pharmaceutical companies in developing innovative drugs.

Reference link:https://www.drugs.com